These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38320604)

  • 21. The Investigation and Prediction of Voriconazole-Associated Hepatotoxicity under Therapeutic Drug Monitoring
    Ma J; Wang Y; Ma S; Li J
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38082975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
    Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
    J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.
    Amigues I; Cohen N; Chung D; Seo SK; Plescia C; Jakubowski A; Barker J; Papanicolaou GA
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):46-52. PubMed ID: 20053331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.
    Cabral-Galeano E; Ruiz-Camps I; Len-Abad O; Pou-Clavé L; Sordé-Masip R; Meije-Castillo Y; Blanco-Grau A; Barba-Suñol P; Monforte-Torres V; Román-Broto A; Pahissa-Berga A; Gavaldà-Santapau J
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):298-302. PubMed ID: 25459191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care.
    van Wanrooy MJ; Rodgers MG; Span LF; Zijlstra JG; Uges DR; Kosterink JG; van der Werf TS; Alffenaar JW
    Ther Drug Monit; 2016 Jun; 38(3):313-8. PubMed ID: 26845112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.
    Hashemizadeh Z; Badiee P; Malekhoseini SA; Raeisi Shahraki H; Geramizadeh B; Montaseri H
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
    Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
    Wang X; Zhao J; Wen T; Liao X; Luo B
    Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment.
    Florent A; Gandia P; Seraissol P; Chatelut E; Houin G
    Ther Drug Monit; 2014 Dec; 36(6):752-8. PubMed ID: 24819971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.
    Vanstraelen K; Maertens J; Augustijns P; Lagrou K; de Loor H; Mols R; Annaert P; Malfroot A; Spriet I
    Clin Pharmacokinet; 2015 Nov; 54(11):1151-60. PubMed ID: 25910879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
    Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
    J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia.
    Zhou PY; Lim TP; Tang SLS; Liew Y; Chua SGN; Lim LLC; Lee HLW; Tan SX; Lai OF; Tan TT; Wong GC; Kwa LHA
    J Glob Antimicrob Resist; 2020 Jun; 21():427-433. PubMed ID: 31846723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
    Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
    Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
    Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
    BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
    Dolton MJ; Ray JE; Chen SC; Ng K; Pont LG; McLachlan AJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4793-9. PubMed ID: 22751544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.